Checkpoint Therapeutics, Inc.
NASDAQ:CKPT
4.1 (USD) • At close April 25, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.041 | 0.103 | 0.192 | 0.268 | 1.069 | 1.708 | 3.506 | 1.725 | 2.57 | 0.59 |
| Cost of Revenue
| 0 | 43.566 | 49.825 | 48.453 | 16.352 | 19.325 | 33.654 | 19.081 | 20.267 | 11.323 |
| Gross Profit
| 0.041 | -43.463 | -49.633 | -48.185 | -15.283 | -17.617 | -30.148 | -17.356 | -17.697 | -10.733 |
| Gross Profit Ratio
| 1 | -421.971 | -258.505 | -179.795 | -14.297 | -10.314 | -8.599 | -10.061 | -6.886 | -18.192 |
| Reseach & Development Expenses
| 36.152 | 43.566 | 49.825 | 48.453 | 16.352 | 19.325 | 33.654 | 19.081 | 20.267 | 11.323 |
| General & Administrative Expenses
| 20.063 | 8.685 | 8.7 | 8.538 | 7.918 | 7.233 | 6.592 | 5.419 | 4.467 | 2.488 |
| Selling & Marketing Expenses
| 0 | 0 | 0.4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 20.063 | 8.685 | 8.7 | 8.538 | 7.918 | 7.233 | 6.592 | 5.419 | 4.467 | 2.488 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0.225 | 0 | 0 | 0 |
| Operating Expenses
| 56.215 | 52.251 | 58.525 | 56.991 | 24.27 | 26.558 | 40.246 | 24.5 | 24.734 | 13.811 |
| Operating Income
| -56.174 | -52.148 | -58.333 | -56.723 | -23.201 | -24.85 | -36.74 | -22.775 | -22.164 | -13.221 |
| Operating Income Ratio
| -1,370.098 | -506.291 | -303.818 | -211.653 | -21.703 | -14.549 | -10.479 | -13.203 | -8.624 | -22.408 |
| Total Other Income Expenses Net
| -0.066 | 0.301 | -4.291 | 0.053 | 0.12 | 0.136 | 0.373 | 0.098 | -0.297 | -0.671 |
| Income Before Tax
| -56.24 | -51.847 | -62.624 | -56.67 | -23.081 | -24.714 | -36.367 | -22.677 | -22.461 | -13.892 |
| Income Before Tax Ratio
| -1,371.707 | -503.369 | -326.167 | -211.455 | -21.591 | -14.47 | -10.373 | -13.146 | -8.74 | -23.546 |
| Income Tax Expense
| 0 | 0 | 4.291 | -0.053 | -0.12 | -0.136 | -0.521 | -22.677 | -22.117 | 0.233 |
| Net Income
| -56.24 | -51.847 | -66.915 | -56.617 | -22.961 | -24.578 | -36.367 | -22.677 | -22.461 | -13.892 |
| Net Income Ratio
| -1,371.707 | -503.369 | -348.516 | -211.257 | -21.479 | -14.39 | -10.373 | -13.146 | -8.74 | -23.546 |
| EPS
| -1.42 | -2.77 | -7.57 | -7.45 | -4.11 | -6.96 | -12.74 | -10.03 | -10.43 | -5.69 |
| EPS Diluted
| -1.42 | -2.77 | -7.57 | -7.45 | -4.11 | -6.96 | -12.74 | -10.03 | -10.43 | -5.69 |
| EBITDA
| -56.174 | -52.148 | -58.333 | -56.723 | -23.201 | -24.85 | -36.74 | -22.677 | -22.117 | -13.219 |
| EBITDA Ratio
| -1,370.098 | -506.291 | -303.818 | -211.653 | -21.703 | -14.549 | -10.479 | -13.146 | -8.606 | -22.405 |